Clinical Trial Update: A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 feasibility trial evaluating nivolumab added to neoadjuvant CF or DCF chemotherapy in locally advanced esophageal squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Center, Japan | Conditions: Locally Advanced Esophageal Squamous Cell Carcinoma | Phase 1 | Status: COMPLETED